- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04396860
Testare l'uso dei farmaci immunoterapici Ipilimumab e Nivolumab Plus radioterapia rispetto al trattamento abituale (temozolomide e radioterapia) per il glioblastoma non metilato MGMT di nuova diagnosi
Uno studio randomizzato di fase II/III in aperto su ipilimumab e nivolumab rispetto a temozolomide in pazienti con glioblastoma non metilato di nuova diagnosi di MGMT (tumore O-6-metilguanina DNA metiltransferasi)
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Stati Uniti, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Stati Uniti, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Stati Uniti, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Stati Uniti, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Stati Uniti, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Stati Uniti, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Stati Uniti, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Stati Uniti, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Stati Uniti, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Stati Uniti, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Stati Uniti, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Stati Uniti, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Stati Uniti, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Stati Uniti, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Stati Uniti, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Stati Uniti, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Stati Uniti, 80210
- AdventHealth Porter
-
Littleton, Colorado, Stati Uniti, 80122
- AdventHealth Littleton
-
Parker, Colorado, Stati Uniti, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06102
- Hartford Hospital
-
New Britain, Connecticut, Stati Uniti, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Stati Uniti, 19958
- Beebe Medical Center
-
Millville, Delaware, Stati Uniti, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Stati Uniti, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stati Uniti, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Stati Uniti, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Stati Uniti, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Stati Uniti, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Stati Uniti, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Stati Uniti, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Stati Uniti, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stati Uniti, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Stati Uniti, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Stati Uniti, 96813
- Island Urology
-
Kailua, Hawaii, Stati Uniti, 96734
- Castle Medical Center
-
Lihue, Hawaii, Stati Uniti, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Stati Uniti, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Stati Uniti, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stati Uniti, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stati Uniti, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stati Uniti, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stati Uniti, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Stati Uniti, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Stati Uniti, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Stati Uniti, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stati Uniti, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Stati Uniti, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Stati Uniti, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Stati Uniti, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stati Uniti, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Stati Uniti, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Stati Uniti, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Stati Uniti, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Stati Uniti, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Stati Uniti, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stati Uniti, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Stati Uniti, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stati Uniti, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Urbana, Illinois, Stati Uniti, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Stati Uniti, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Stati Uniti, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stati Uniti, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Stati Uniti, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Stati Uniti, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Stati Uniti, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Stati Uniti, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Stati Uniti, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Stati Uniti, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Stati Uniti, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Stati Uniti, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Stati Uniti, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Stati Uniti, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stati Uniti, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Stati Uniti, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Stati Uniti, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Stati Uniti, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stati Uniti, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stati Uniti, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Stati Uniti, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Stati Uniti, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Stati Uniti, 48503
- Hurley Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Stati Uniti, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stati Uniti, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Stati Uniti, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Stati Uniti, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Stati Uniti, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Stati Uniti, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Stati Uniti, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Stati Uniti, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Stati Uniti, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Stati Uniti, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Stati Uniti, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stati Uniti, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Stati Uniti, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stati Uniti, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
Stillwater, Minnesota, Stati Uniti, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Stati Uniti, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Stati Uniti, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stati Uniti, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Stati Uniti, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Stati Uniti, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stati Uniti, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Stati Uniti, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Stati Uniti, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Stati Uniti, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Stati Uniti, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Stati Uniti, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Stati Uniti, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Stati Uniti, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Stati Uniti, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Stati Uniti, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Stati Uniti, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Stati Uniti, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stati Uniti, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Stati Uniti, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Stati Uniti, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stati Uniti, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Stati Uniti, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Stati Uniti, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stati Uniti, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Stati Uniti, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Stati Uniti, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Stati Uniti, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Stati Uniti, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Stati Uniti, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Stati Uniti, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Stati Uniti, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Stati Uniti, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Stati Uniti, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Stati Uniti, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Stati Uniti, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Stati Uniti, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Stati Uniti, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Stati Uniti, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Stati Uniti, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Stati Uniti, 84321
- Logan Regional Hospital
-
Murray, Utah, Stati Uniti, 84107
- Intermountain Medical Center
-
Ogden, Utah, Stati Uniti, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Stati Uniti, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Stati Uniti, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Stati Uniti, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stati Uniti, 84143
- LDS Hospital
-
St. George, Utah, Stati Uniti, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Stati Uniti, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Stati Uniti, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Stati Uniti, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Stati Uniti, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Stati Uniti, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Stati Uniti, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Stati Uniti, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Stati Uniti, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Stati Uniti, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stati Uniti, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Stati Uniti, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Stati Uniti, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stati Uniti, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Stati Uniti, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Stati Uniti, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Stati Uniti, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Stati Uniti, 53227
- Aurora West Allis Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Altri nomi:
Ancillary studies Given PO
Altri nomi:
Undergo radiation therapy
Altri nomi:
Undergo contrast-enhanced brain MRI
Altri nomi:
Wear Optune device
Altri nomi:
|
|
Sperimentale: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Altri nomi:
Given IV
Altri nomi:
Ancillary studies Given IV
Altri nomi:
Undergo radiation therapy
Altri nomi:
Undergo contrast-enhanced brain MRI
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Lasso di tempo: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Lasso di tempo: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Lasso di tempo: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Lasso di tempo: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Lasso di tempo: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Lasso di tempo: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Lasso di tempo: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Lasso di tempo: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
OS (se lo studio si interrompe nella Fase II)
Lasso di tempo: Al termine della fase II di studio
|
Al termine della fase II di studio
|
|
|
Tumor Biomarker Analyses
Lasso di tempo: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Lasso di tempo: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Andrew B Lassman, NRG Oncology
Pubblicazioni e link utili
Pubblicazioni generali
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Glioma
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Gliosarcoma
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Tecniche investigative
- Terapie
- Azoli
- Azioni farmacologiche
- Azioni e usi chimici
- Fattori biologici
- Fenomeni fisici
- Dacarbazine
- Triazenes
- Imidazoli
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Usi speciali di sostanze chimiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Recettori, superficie cellulare
- Proteine della membrana
- Antigeni
- Antigeni, superficie
- Biomarcatori
- Usi diagnostici di sostanze chimiche
- Recettori, immunologici
- Antigeni, differenziazione, T-linfocita
- Antigeni, differenziazione
- Proteine del checkpoint immunitario
- Recettori costimolativi e inibitori delle cellule T.
- Temozolomide
- Nivolumab
- Ipilimumab
- Radioterapia
- Radiazione
- Spettroscopia di risonanza magnetica
- Media di contrasto
- Antigene CTLA-4
Altri numeri di identificazione dello studio
- NCI-2020-03404
- U10CA180868 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2020-03404 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Altro identificatore: CTEP)
- NRG-BN007 (Altro identificatore: NRG Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .